Clinical Trial Update: Vorinostat Dose-escalation After Allogeneic Hematopoietic Cell Transplantation [Phase 1]

View source ↗

Summary

A Phase 1 dose-escalation study of vorinostat after allogeneic hematopoietic cell transplantation is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Juvenile Myelomonocytic Leukemia
• Mixed Phenotype Acute Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• Zolinza (vorinostat)

Snippet

Sponsor: Johns Hopkins All Children's Hospital | Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes | Phase 1 | Status: ACTIVE_NOT_RECRUITING